The Obesity ETF (SLIM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Novo Nordisk Stock Drops on New Obesity Drug Finding. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed significant mean placebo-adjusted weight loss up to 11.3% without plateau after 12 weeks, with phase 2b and monthly dosing data expected in 2025. MET-233i, a long-acting amylin analog being explored in a phase 1 study, is expected to have a data release in mid-2025.
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders.
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and related conditions. The firm's lead candidate, MET-097i, is in Phase 2b trials, with preliminary results expected by mid-2025, but faces intense competition. Management plans to use IPO proceeds for clinical trials and operational expenses, with funds expected to last until 2027.
Pharma Stock Pops on Upbeat Obesity Drug Trial Results
Novo Nordisk A/S (NYSE:NVO) today announced positive early-stage trial results for its amycretin obesity drug.
Viking Therapeutics: Investors Meeting Reality Of The Obesity Market
Viking Therapeutics has promising clinical developments in obesity, NASH/MASH, and X-ALD, but its stock fell 50% due to broader GLP-1 market concerns. Despite Eli Lilly's Q4 miss, the long-term outlook for GLP-1 and obesity markets remains strong, suggesting VKTX's sell-off was unjustified. VKTX's valuation is appealing post-sell-off, with potential blockbuster drugs VK2735 and VK2809 targeting large, lucrative markets.
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Few drugs have generated as much excitement as Novo Nordisk's (NVO -5.27%) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 diabetes.
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing (Correct)
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026.
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026.
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
On Wednesday, Novo Nordisk A/S NVO and Valo Health, Inc. entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Tyrzepatide seems more effective than semaglutide, but the market for slimming drugs is quite large for both. Both companies have a dominant position in their industry and a solid financial position, but Eli Lilly seems too pricey right now. In contrast, Novo Nordisk seems rather cheap given. The number of obese people in the world is bound to increase unless there is a radical change in habits. This factor is the main long-term growth driver.
Lilly's Obesity Drug Zepbound To Be Key Health Cost Driver For 2025
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers, employers and government health programs who cover it in 2025.
